Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Tencent Music Entertainment Group - ADR — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Tencent Music Entertainment Group - ADR trades at $8.43 (market cap $16.09B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Tencent Music Entertainment Group - ADR pays a 2.75% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TME | |
|---|---|---|
Market Cap | $29.60B | $16.09B |
Sector | Health | Media |
52-Week High | $491.22 | $26.36 |
52-Week Low | $205.48 | $8.16 |
Enterprise Value | $27.56B | $14.05B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
TME stock trades at $8.45, down 14.65% in the last session amid mixed earnings results. The company reported Q2 2026 revenue growth of 6% year-over-year but faces slowing operational growth and competitive pressures. Valuation metrics appear reasonable with a P/E of 10.29 and P/S of 2.71, while profitability remains strong with a net income margin of 26.28%. Technical indicators signal a bearish trend, with the stock near key support levels.
The outlook is cautious; while TME's fundamentals are solid with robust cash flow and profitability, near-term headwinds from competition and market sentiment pose risks. Analyst consensus is divided, with 46% buy ratings but 50% hold, reflecting uncertainty over growth sustainability. Investors should weigh the attractive valuation against execution risks in a challenging environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
